Updates in First-Line Systemic Therapy for Advanced HCC: The IMbrave150 Trial
Julio Gutierrez, MD, and Ghassan K. Abou-Alfa, MD, discuss the results of the IMbrave150 study investigating atezolizumab plus bevacizumab in the first-line setting for advanced HCC.
EP: 1.Overview of Hepatocellular Carcinoma (HCC)
EP: 2.Diagnosing Patients With Hepatocellular Carcinoma
EP: 3.Factoring Stage and Hepatic Function Into Treatment Decision-Making for HCC
EP: 4.Treatment Approaches for Patients With Early-Stage HCC
EP: 5.The Role of Adjuvant Therapy in Patients With Early-Stage HCC
Now Viewing
EP: 6.Updates in First-Line Systemic Therapy for Advanced HCC: The IMbrave150 Trial
EP: 7.Updates in First-Line Systemic Therapy for Advanced HCC: The HIMALAYA Study
EP: 8.Optimal Sequencing in Patients With Advanced HCC
EP: 9.Safety Profiles of Available Therapies in Advanced HCC
EP: 10.The Future of HCC Treatment
EP: 11.First-Line Systemic Treatment Options for Patients With Advanced HCC
EP: 12.Tremelimumab Plus Durvalumab in Patients With Advanced HCC: The HIMALAYA Study
EP: 13.Key Safety Outcomes From Updated Analysis of HIMALAYA Trial in Advanced HCC
EP: 14.The CELESTIAL Study: Cabozantinib Monotherapy in Advanced HCC Treatment
EP: 15.Safety and Efficacy Data From the Retrospective Analysis of the CELESTIAL Study in Advanced HCC
EP: 16.Future of Advanced HCC Treatment
Related Videos
Related Content
